|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CA |
First Approval Date01 Jan 1985 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
YS001胶囊治疗晚期恶性实体瘤患者的开放标签、多中心、剂量递增和扩展I期临床试验
[Translation] An open-label, multicenter, dose-escalation and expansion phase I clinical trial of YS001 capsules in patients with advanced malignant solid tumors
评估YS001治疗晚期恶性实体瘤患者的安全性和耐受性,探索剂量限制毒性(DLT)和确定最大耐受剂量(MTD)
[Translation] To evaluate the safety and tolerability of YS001 in the treatment of patients with advanced malignant solid tumors, explore dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD)
重组人血管内皮抑素注射液在中国晚期实体瘤患者中单次及多次静脉滴注给药的耐受性及药代动力学研究
[Translation] Study on the tolerability and pharmacokinetics of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors
主要目的是考察重组人血管内皮抑素注射液在中国晚期实体瘤患者中单次及多次静脉滴注给药的耐受性,次要目的是评价重组人血管内皮抑素注射液在中国晚期实体瘤患者中单次及多次静脉滴注给药的药代动力学特征。
[Translation] The primary objective was to investigate the tolerability of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors. The secondary objective was to evaluate the pharmacokinetic characteristics of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors.
重组人血管内皮抑素注射液联合NP对照安慰剂联合NP治疗初治晚期非小细胞肺癌患者的三期临床研究
[Translation] Phase III clinical study of recombinant human endostatin injection combined with NP versus placebo combined with NP in the treatment of patients with newly diagnosed advanced non-small cell lung cancer
评价重组人血管内皮抑素注射液联合长春瑞滨/顺铂(NP)化疗方案较单纯NP方案在治疗IV期非小细胞肺癌病人(UICC 第7版NSCLC分期定义)的临床生存期获益优势。观察重组人血管内皮抑素注射液联合化疗方案在晚期非小细胞肺癌病人中的安全性。
[Translation] To evaluate the clinical survival benefit of recombinant human endostatin injection combined with vinorelbine/cisplatin (NP) chemotherapy compared with NP alone in the treatment of patients with stage IV non-small cell lung cancer (UICC 7th edition NSCLC staging definition). To observe the safety of recombinant human endostatin injection combined with chemotherapy in patients with advanced non-small cell lung cancer.
100 Clinical Results associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
0 Patents (Medical) associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
100 Deals associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
100 Translational Medicine associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.